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Serine + H4folate → Glycine + CH2 –H4folate

Abstract
Methylenetetrahydrofolate reductase catalyzes the reduction of methylenetetrahydrofolate to methyltetrahydrofolate, which serves as the methyl donor for the conversion
of homocysteine to methionine in the reaction catalyzed
by methionine synthase. Recent studies have provided
evidence for association of a common polymorphism of
methylenetetrahydrofolate reductase with elevated levels of blood homocysteine, a metabolite correlated with increased cardiovascular risk in humans. In this chapter, we
review earlier studies on the properties of the mammalian
enzyme, interpreting these observations in the light of the
deduced amino acid sequence for the human enzyme. The
catalytic portion of the human enzyme shows significant
sequence homologies with methylenetetrahydrofolate reductase from bacterial sources, and in particular mutations
that are known to cause elevated blood homocysteine levels in humans affect residues that are conserved in the bacterial enzyme. Thus we believe that studies of mutant E.
coli proteins will provide valuable information on the consequences of human mutations of equivalent residues.

(1)

CH2 –H4folate + NADPH → CH3-H4folate + NADP+ (2)
CH3-H4folate + Homocysteine → H4folate + Methionine
(3)
The combined action of these three enzymes results in
the methylation of homocysteine by transfer of a methyl
group derived from the β-carbon of serine. Methionine
can be converted to adenosylmethionine (AdoMet)
by adenosylmethionine synthetase, as shown in (4).
AdoMet is an activated methyl donor, and serves to
provide methyl groups in a wide variety of biological
methylation reactions.
Methionine + ATP → AdoMet + tripolyphosphate (4)
Methylenetetrahydrofolate reductase has been purified from a variety of bacterial and mammalian sources
and has been shown to contain enzyme-bound FAD as
a prosthetic group [1—6]. The flavin plays an essential role in the catalytic reaction. In the porcine enzyme,
which has been purified to homogeneity [6] and extensively studied, NADPH stoichiometrically
reduces the flavin as indicated in (5).

Properties of Mammalian Methylenetetrahydrofolate
Reductase
The conversion of homocysteine to methionine requires a sequence of three enzymatic reactions, which
are catalyzed by serine hydroxymethyltransferase (41), methylenetetrahydrofolate reductase (MTHFR [4-2]),
and cobalamin-dependent methionine synthase (4-3),
respectively.

FADPH + E ∙ FADox → NADP+ + E ∙ FADred

(5)

This reaction is irreversible both in vivo and in vitro [7], and imparts irreversibility to the entire reaction
shown in (2). In the physiologic reaction, the reduced
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enzyme—bound flavin is oxidized by methylenetetrahydrofolate (CH2-H4folate) in a reaction that is freely reversible [6], as shown in (6).
E ∙ FADred + CH2-H4folate ↔ E ∙ FADox + CH3-H4folate
(6)
The reversibility of the reaction shown in (6) has been
exploited in the standard assay for MTHFR [1,2,5], in
which oxidation of [5-3H methyl]CH3-H4folate to CH2H4folate is coupled to the reduction of menadione to
menadiol, and the resultant CH2-H4folate is subjected
to acid decomposition in the presence of dimedone.
In acid, CH2-H4folate decomposes to form [3H]-formaldehyde, and the formaldehyde-dimedone complex
is extracted into toluene for quantitation of product
formation.
Stereochemical and kinetic analyses of the reactions
catalyzed by the porcine enzyme have shown that both
NADPH and CH2-H4folate react at the si face of the enzyme-bound flavin [8], which is depicted in Figure 1.
While X-ray structures have been determined for a variety of NADPH-dependent flavoprotein oxidoreductases
[9—11], the majority of these proteins bind one or more
of their substrates at the re face of the flavin [12]. Thus,
the sequence motifs that have been identified in these
proteins as being associated with flavin binding may
not be the same for MTHFR.
Kutzbach and Stokstad [5] initially demonstrated
that mammalian MTHFR activity is regulated by the
AdoMet/adenosylhomocysteine ratio, with AdoMet inhibiting enzyme activity and inhibition being relieved
by adenosylhomocysteine. Thus, the activity of MTHFR
is adjusted in accord with the demand for methyl groups
for biological methylation reactions. AdoMet binding to
MTHFR results in a conformational change to a form of
enzyme with decreased affinity for NADPH. NADPH
and AdoMet play antagonistic roles in this regulation,
with NADPH recruiting the active forms of the enzyme,
and AdoMet recruiting inactive forms [13].
The native porcine MTHFR is a homodimer of 77
kDa subunits, but when shadowed preparations of the
individual dimers are viewed in the scanning transmission electron microscope they show four clear lobes
of density, rather than two [14]. These observations
suggested that each subunit might contain two distinct
regions. Limited proteolysis of the native enzyme with
trypsin indeed results in cleavage of the 7 7 kDa subunit into 40 and 37 kDa fragments, and cleavage is associated with the loss of inhibition by AdoMet, but the
activity of the enzyme is unaffected [14]. Photoaffinity
labeling of the enzyme with 8-azido-S-adenosylmethionine results in specific labeling of the C-terminal 37
kDa region [15].

Figure 1. The structure of the isoalloxazine ring of flavin
adenine dinucleotide as viewed from the si face, where
both substrates of porcine liver methylenetetrahydrofolate
reductase, NAD(P)H and CH2-H4folate, react.

The isolation of a cDNA coding for the human
MTHFR and its recent sequencing [16,17] have provided considerable insight into the organization of the
enzyme. The deduced amino acid sequence for this
cDNA is shown in Figure 2, and corresponds to a molecular mass of 74,546 kDa. Underlined in Figure 2 are
residues corresponding to peptides isolated from homogeneous porcine enzyme and sequenced by Edman degradation. The N-terminal sequence of the porcine enzyme does not appear in the human cDNA,
which may indicate that the cDNA isolated codes for a
smaller isozyme of MTHFR or perhaps lacks sequence
at the 5′-end.
In one experiment, the native porcine enzyme was
first digested with trypsin and the N- and C-terminal
fragments were separated by gel electrophoresis under
denaturing conditions. The isolated fragments were
cleaved with lysyl endoprotease (LysC), which cleaves
the amide bond on the C-terminal side of lysyl residues. Peptides that were derived from the 40 kDa Nterminal fragment correspond to residues 61-94, 219240, and 337-351 [16], while peptides that were derived
from the 37 kDa C-terminal fragment correspond to
residues 374-394, 420-445, 469-492, 531-543, and 598628 (JS Sumner and RG Matthews, unpublished data).
These sequences define the cleavage point between the
40 and 37 kDa fragments as lying between residues 351
and 374. The sequence in this region with the greatest
hydrophilicity and surface probability is K357RREED,
and this is the probable site of cleavage of the native
enzyme. The predicted mass of the C-terminal fragment generated by cleavage between lysine357 and arginine358 is 34,863 Da, in moderately good agreement
with the 37 kDa mass observed after cleavage of the
porcine enzyme.
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Figure 2. Alignment of the deduced amino-acid sequence of human methylenetetrahydrofolate reductase [16,17], designated mthfr, with the deduced amino acid sequences of the MetF proteins from E. coli [19] and S. typhimurium [20],
designated ecometF and stymetF, respectively. Underlined residues indicate identities with residues in peptides isolated from porcine liver methylenetetrahydrofolate reductase. Residues shown in bold are identical in all three deduced sequences. Bullets indicate the locations of three mutations that are associated with homocysteinemia in humans
and that affect conserved residues in the aligned sequences. The numbering of the mthfr amino acid sequence assumes
that the ATG codon in the cDNA beginning at nt 13 of the published sequence [16] is the initiator site for translation of
the protein.

Properties of the Bacterial Methylenetetrahydrofolate
Reductase Enzymes
Figure 2 also shows the alignment of the deduced
amino acid sequence of human MTHFR with the sequences of the methylenetetrahydrofolate reductases
from Escherichia coli and Salmonella typhimurium. These
aligned sequences show 24% identity, so that the three-

dimensional structures of the bacterial enzymes and
the N-terminal region of the human enzyme are almost certainly highly similar. The MTHFR from Escherichia coli was initially characterized by Buchanan and
his colleagues [3]. This enzyme was shown to be a flavoprotein, and was shown to catalyze the reduction of
CH2-H4folate to CH3-H4folate. In contrast to the mammalian enzymes, the bacterial enzyme activity is not
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regulated by adenosylmethionine, in agreement with
the lack of a C-terminal regulatory domain. This protein is encoded by the metF gene in both E. coli and S.
typhimurium. The metF gene from both organisms has
been sequenced [19,20]. We have succeeded in constructing an expression vector for overproduction of
MTHFR from Escherichia coli plasmid pEJ3-1B, which
contains the metF gene in a pBR322 plasmid [20]. In
our vector, pCAS-5, the MTHFR coding sequence is
placed under the control of the trc promoter, and approximately 20% of the total cellular protein is MTHFR
when cells are grown in the presence of IPTG. We have
recently purified the wild type bacterial enzyme to homogeneity, and have confirmed that the MTHFR protein is a flavoprotein. The homogenous enzyme exhibits both CH3-H4folate-menadione oxidoreductase
activity (7),
CH3-H4folate + menadione → CH2-H4folate + menadiol
(7)
and NADH-menadione oxidoreductase activity (8).
NADH + menadione → NAD+ + menadiol

(8)

Initial studies of partially purified MTHFR enzyme
had indicated that NADH could supply reducing equivalents for the reduction of CH2-H4folate, but further
purification of the enzyme by Katzen and Buchanan
resulted in the loss of NADH-CH2 -H4folate oxidoreductase activity [3]. However, in our enzyme preparations
NADH-menadione oxidoreductase activity copurifies
with CH3-H4folate-menadione oxidoreductase activity,
and we presume that the physiologic reaction is given
by (9).
NADH + CH2-H4folate → NAD+ + CH3-H4folate

et al. in
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Mutations Associated with Homocysteinemia in
Humans and the Phenotypes of the Corresponding
Bacterial Mutations
A number of mutations of human MTHFR that are
associated with human disease have now been identified [16,17,21]. A subset of these mutations affect residues that are identical in the sequences of the bacterial enzymes aligned in Figure 2. These mutations
include Arg157Gln [16] and Thr227Met, as well as the
polymorphism Ala222Val. In humans, the Thr227Met
mutation in a homozygous state is associated with
extremely low levels of activity (0–3%) and onset of
symptoms within the first year after birth [21]. Thus
far, the only patients with the Arg157Gln mutation are
heterozygotes, with an uncharacterized second mutation [16,21]. These patients have >6% residual activity
and develop symptoms only during or after the second
decade of life.
The Ala222Val polymorphism is thought to be associated with mild homocysteinemia in humans [17].
Homocysteinemia has been identified as an independent risk factor for cardiovascular disease [22]. Indeed, Kang and his colleagues [23] have described
the association of a mild MTHFR deficiency, with increased thermolability, with increased risk for coronary artery disease. At the time this work was published, the sequence of MTHFR was not known, and so
the mutation(s) responsible for this phenotype could
not be not identified. Because the catalytic mechanism
and tertiary structure of the N-terminal region of the
human enzyme is likely to be very similar to those of
the bacterial enzymes, we have undertaken the construction and expression of mutations that correspond
to Arg157Gln, Thr227Met, and Ala222 Val in the E. coli
enzyme. Characterization of these mutant enzymes is
now in progress.

(9)

Thus, the bacterial enzymes are able to bind FAD
and catalyze the transfer of reducing equivalents from
NADH to the enzyme-bound flavin and from reduced
flavin to CH2-H4folate. Since these enzymes are only
~33kDa (296 amino acids), the corresponding region
of the human enzyme is likely to contain the residues
necessary for FAD, NADPH, and CH2-H4folate binding. Thus the catalytic domain of the human enzyme is
probably located in the N-terminal 40kDa region, while
regulation by AdoMet is likely to require the C-terminal domain. The sequence alignment indicates several highly conserved regions of sequence, which are
likely to contain residues critical to the binding of substrates and FAD, and to catalysis of oxidoreduction of
the substrates.
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